Sign In
Buy ANRGF
Anaergia Earnings Calls
| Release date | Nov 11, 2025 |
| EPS estimate | -$0.0287 |
| EPS actual | -$0.0287 |
| Revenue estimate | 65M |
| Revenue actual | 36.905M |
| Revenue Surprise | -43.22% |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.0367 |
| EPS actual | -$0.0302 |
| EPS Surprise | 17.78% |
| Revenue estimate | 33M |
| Revenue actual | 23.679M |
| Revenue Surprise | -28.25% |
| Release date | May 13, 2025 |
| EPS estimate | -$0.0486 |
| EPS actual | -$0.0140 |
| EPS Surprise | 71.13% |
| Revenue estimate | 27M |
| Revenue actual | 17.468M |
| Revenue Surprise | -35.30% |
| Release date | Mar 31, 2025 |
| EPS estimate | -$0.0417 |
| EPS actual | -$0.0758 |
| EPS Surprise | -81.89% |
| Revenue estimate | 22.932M |
| Revenue actual | 23.666M |
| Revenue Surprise | 3.20% |
Last 4 Quarters for Anaergia
Below you can see how ANRGF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 31, 2025 |
| Price on release | $0.590 |
| EPS estimate | -$0.0417 |
| EPS actual | -$0.0758 |
| EPS surprise | -81.89% |
| Date | Price |
|---|---|
| Mar 25, 2025 | $0.685 |
| Mar 26, 2025 | $0.685 |
| Mar 27, 2025 | $0.685 |
| Mar 28, 2025 | $0.685 |
| Mar 31, 2025 | $0.590 |
| Apr 01, 2025 | $0.652 |
| Apr 02, 2025 | $0.652 |
| Apr 03, 2025 | $0.620 |
| Apr 04, 2025 | $0.680 |
| 4 days before | -13.85% |
| 4 days after | 15.27% |
| On release day | 10.42% |
| Change in period | -0.694% |
| Release date | May 13, 2025 |
| Price on release | $0.85 |
| EPS estimate | -$0.0486 |
| EPS actual | -$0.0140 |
| EPS surprise | 71.13% |
| Date | Price |
|---|---|
| May 07, 2025 | $0.85 |
| May 08, 2025 | $0.85 |
| May 09, 2025 | $0.85 |
| May 12, 2025 | $0.85 |
| May 13, 2025 | $0.85 |
| May 14, 2025 | $0.85 |
| May 15, 2025 | $0.85 |
| May 16, 2025 | $0.85 |
| May 19, 2025 | $0.682 |
| 4 days before | 0% |
| 4 days after | -19.70% |
| On release day | 0% |
| Change in period | -19.70% |
| Release date | Aug 12, 2025 |
| Price on release | $0.96 |
| EPS estimate | -$0.0367 |
| EPS actual | -$0.0302 |
| EPS surprise | 17.78% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $1.00 |
| Aug 07, 2025 | $1.00 |
| Aug 08, 2025 | $0.93 |
| Aug 11, 2025 | $0.97 |
| Aug 12, 2025 | $0.96 |
| Aug 13, 2025 | $0.99 |
| Aug 14, 2025 | $0.99 |
| Aug 15, 2025 | $1.00 |
| Aug 18, 2025 | $1.04 |
| 4 days before | -3.92% |
| 4 days after | 8.35% |
| On release day | 3.04% |
| Change in period | 4.10% |
| Release date | Nov 11, 2025 |
| Price on release | $1.85 |
| EPS estimate | -$0.0287 |
| EPS actual | -$0.0287 |
| Date | Price |
|---|---|
| Nov 05, 2025 | $1.61 |
| Nov 06, 2025 | $1.77 |
| Nov 07, 2025 | $1.76 |
| Nov 10, 2025 | $1.85 |
| Nov 11, 2025 | $1.85 |
| Nov 12, 2025 | $1.85 |
| Nov 13, 2025 | $1.76 |
| Nov 14, 2025 | $1.76 |
| Nov 17, 2025 | $1.61 |
| 4 days before | 14.91% |
| 4 days after | -12.97% |
| On release day | 0% |
| Change in period | 0% |
Anaergia Earnings Call Transcript Summary of Q3 2025
Q3 2025 was a turning point for Anaergia: revenue rose 77% year-over-year to $51.4M, gross profit increased to $14.8M and gross margin expanded to 28.8%. SG&A declined ~16% y/y, net loss narrowed to $0.5M, and adjusted EBITDA turned positive at $2.6M (first positive quarter in over two years). The company’s revenue backlog reached $287M at quarter-end (up from $103M at the start of the year), driven by signed capital sales in Italy, North America and a new multi-site framework in Spain (~$184M framework, with the first project added to backlog). Operational execution and repeat business (common scopes, preferred vendors, turnkey projects) are cited as the main drivers of margin improvement. Key ongoing projects include Livorno (Italy), multiple Italian follow-on orders ($44M expected revenue), PreZero in Spain (~$7M), the multi-site Spanish program, Tuas View Basin in Singapore (mid-construction), and a Riverside, CA RNG project with conditional financing (~$39M expected revenue). Management emphasizes the capital-light strategy, recurring long-term O&M opportunities, geographic diversification, and continued focus on operational discipline. The company notes industry tailwinds but reminds investors that forward-looking statements are subject to risks and uncertainties.
